A video accompanying this release is available at http://globenewswire.com/
The study found that 64 percent of subjects found pain relief within two hours of taking LipiGesic™ M. The study concludes that sublingual feverfew/ginger appears safe and effective as a first-line treatment for a population of migraineurs who frequently experience mild headache prior to the onset of moderate to severe headache.
"We are extremely pleased with the results of the independent study of LipiGesic™ M," said PuraMed BioScience CEO Russell Mitchell. "This study positions LipiGesic™ M as a highly effective first-line therapy for migraines. We are confident that we are introducing the best discovery in recent history for the relief of migraines."
Mitchell continued, "In addition to the higher efficacy rate, the study subjects reported minimal to no side effects. The study also indicates that LipiGesic™ M is safe to combine with other medications and does not require a prescription. In this time when healthcare costs continue to rise, we are pleased to offer this superior migraine treatment at a drastically more affordable rate—at least 75 percent less expensive when compared to leading prescription medications. It is also important to note that the study states that there remains a need for affordable, effective treatments for migraine sufferers, and that LipiGesic™ M is now recommended as a first-line treatment."
"The timing of the publishing of these study results in June perfectly aligns with National Headache Awareness Month," added Mitchell. "According to the National Headache Foundation, migraines are the most expensive brain disorder, costing the U. S. economy $31 billion in 2010, which is comprised of the cost of treatment and the cost of lost productivity and absenteeism due to this debilitating medical issue. We are pleased to provide this important breakthrough news to the medical community and to the 50 million American consumers that suffer from migraine headaches and are seeking a more effective, accessible and affordable treatment."
This multi-site, double-blind, placebo-controlled study was approved by an independent investigational review board and conducted at three headache centers in the United States. The study, titled "A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic™ M) in the Treatment of Migraine," was conducted by lead investigator Roger K. Cady, MD with the assistance of two additional nationally recognized investigators, Jerome Goldstein, MD, of San Francisco, Calif. and Robert Nett, MD, RPh, of San Antonio, Texas.
Dr. Roger Cady is the founder of Headache Care Center, Clinvest, and Primary Care Education Network. He is a graduate of the Mayo Medical School, and is Board Certified by the American Board of Family Practice. His board certification in Headache Medicine was awarded by the United Council for Neurologic Subspecialties, and he holds a Certificate of Added Qualification through the National Board of Certification in Headache Management. He is a member of multiple medical associations, including the American Medical Association, the National Headache Foundation, the American Headache Society, the American Academy of Pain Management, and the American Academy of Family Physicians. Dr. Cady is best known in the medical community for his pivotal contributions in the field of headache and migraine management. He was the co-recipient of the prestigious Wolff Award in 2000 from the American Headache Society for his research entitled "The Spectrum of Headache". He is well-published and has presented countless lectures and seminars around the world on headache, migraine, and other chronic disorders, and continues to be the principal investigator in numerous multi-center research studies. Dr. Cady currently serves on 12 Advisory Boards and is a member of the Board of Directors for the National Headache Foundation.
To view the abstract for this study, visit the Headache homepage and click on the "Early View" section: http://www.headachejournal.org/
For more information on LipiGesic™ M and to purchase, visit www.LipiGesicM.com.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
Investor Awareness, Inc.
Tony Schor or James Foy, 847-945-2222
North Shore Public Relations, Inc.
Renae Placinski, 847-945-4505
# # #
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/